Mariana Oncology (via Carroll Bio Advisory)
↗Watertown, Massachusetts
Mariana Oncology is a clinical-stage biotechnology company specializing in the development of next-generation radioligand therapies (RLTs) for solid tumors. The company utilizes a proprietary discovery platform to engineer high-affinity peptide-based ligands labeled with alpha- or beta-emitting radionuclides.
In May 2024, Mariana Oncology was acquired by Novartis for $1 billion upfront, with potential milestone payments of up to $750 million. This acquisition was driven by Mariana's innovative pipeline, particularly its lead candidate for small cell lung cancer, and its robust manufacturing and R&D capabilities in the rapidly growing radiopharmaceutical sector.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:N/A (Pre-revenue)
Founded:2021
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Acquired
Total Raised:$250M
Investors:Deep Track Capital, Forbion, RA Capital Management, Atlas Venture, Access Biotechnology, Eli Lilly and Company
STOCK
Exchange:NASDAQ
Ticker:NVS
Market Cap:$230B
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 / IND Cleared
Modalities:Radioligand Therapy (RLT), Peptides, Small molecule, Alpha-emitters (Actinium-225)
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Novartis
Acquired By:Novartis (2024-05-01)
Key Partnerships:Novartis (Acquisition/Integration), NorthStar Medical Radioisotopes (Supply agreement)
COMPETITION
Position:Leader
Competitors:RayzeBio (Acquired by BMS), Fusion Pharmaceuticals (Acquired by AstraZeneca), Point Biopharma (Acquired by Eli Lilly), Perspective Therapeutics, Telix Pharmaceuticals
LEADERSHIP
Key Executives:
Simon Read - CEO
Pamela Carroll - CBO
Scientific Founders:Peter Park, Simon Read
Board Members:Geeta Vemuri, Kevin Forrest
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mariana Oncology (via Carroll Bio Advisory). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.